AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinolone resistance
Number of subjects: 2004
Study 28669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clarithromycin resistance
Number of subjects: 2004
Study 28669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quinolone resistance
Number of subjects: 2004
Study 28669844 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of both sensitive and resistant H. pylori
Number of subjects: 2004
Study 28669895 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVU)
Number of subjects: 597
Study 28669895 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hysterosalpingogram (HSG)
Number of subjects: 597
Study 28669895 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation testing algorithm (TVU and/or modified HSG)
Number of subjects: 597
Study 28669895 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 597
Study 28670237 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (160 mg at week 0, 80 mg at week 2, 40 mg every other week thereafter)
Number of subjects: 20
Study 28670237 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 20
Study 28670355 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-thermal laser therapy
Number of subjects: 0
Study 28673311 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS) for multi-pad stimulation electrode shaping
Number of subjects: 10
Study 28673311 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) using DSS
Number of subjects: 10
Study 28673311 — intervention group
Group type: EXPERIMENTAL
Intervention: DSS in combination with a custom multi-pad electrode design
Number of subjects: 10
Study 28673924 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study 28674057 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 600 mg and maintenance dose (MD) of 400 mg for ECMO patients not receiving continuous renal replacement therapy (CRRT)
Number of subjects: 10
Study 28674057 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 800 mg and maintenance dose (MD) of 600 mg for ECMO patients receiving CRRT
Number of subjects: 10
Study 28674057 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 1,000 mg and maintenance dose (MD) of 800 mg for ECMO patients not receiving CRRT
Number of subjects: 10
Study 28674057 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin loading dose (LD) of 1,200 mg and maintenance dose (MD) of 1,000 mg for ECMO patients receiving CRRT
Number of subjects: 10
Study 28674140 — intervention group
Group type: EXPERIMENTAL
Intervention: BTT1023 (anti-VAP monoclonal antibody)
Number of subjects: 59
Study 28674838 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 127
Study 28674838 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Greater Curvature Plication (LGCP)
Number of subjects: 127
Study 28674838 — intervention group
Group type: COMPARATOR
Intervention: Both LSG and LGCP
Number of subjects: 127
Study 28674870 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (doses converted to haloperidol equivalents)
Number of subjects: 31
Study 28674982 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional pharmaceuticals
Number of subjects: 0
Study 28674982 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Number of subjects: 0
Study 28674982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapies
Number of subjects: 0
Study 28674982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense therapies targeting familial forms of ALS
Number of subjects: 0
Study 28675064 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) subjects
Number of subjects: 237
Study 28675064 — intervention group
Group type: COMPARATOR
Intervention: Cardiac syndrome X (CSX) subjects
Number of subjects: 237
Study 28675524 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal markers and plasma citrulline measured in hypersensitive IBS patients (n=83)
Number of subjects: 167
Study 28675524 — intervention group
Group type: COMPARATOR
Intervention: Fecal markers and plasma citrulline measured in normosensitive IBS patients (n=84)
Number of subjects: 167
Study 28675524 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-poor plasma for serotonin and 5-HIAA in hypersensitive IBS patients (n=53)
Number of subjects: 167
Study 28675524 — intervention group
Group type: COMPARATOR
Intervention: Platelet-poor plasma for serotonin and 5-HIAA in normosensitive IBS patients (n=42)
Number of subjects: 167
Study 28675695 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological intervention (IPI) including cognitive behavioural therapy (CBT) and supportive counselling (SC) for 12 months
Number of subjects: 128
Study 28676102 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive information and communications technology platform (app for reporting symptoms)
Number of subjects: 0
Study 28676102 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 28676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet elimination alone
Number of subjects: 123
Study 28676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowed corticosteroids alone
Number of subjects: 123
Study 28676207 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet elimination and swallowed corticosteroids
Number of subjects: 123
Study 28676207 — intervention group
Group type: COMPARATOR
Intervention: Nonresponders
Number of subjects: 123
Study 28676450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate (UPA) 5mg
Number of subjects: 197
Study 28676651 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing
Number of subjects: 500
Study 28676651 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer testing with a fixed threshold of 0.25 mg/L FEU
Number of subjects: 500
Study 28676651 — intervention group
Group type: COMPARATOR
Intervention: D-dimer and CRP
Number of subjects: 500
Study 28676782 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought Field Therapy (TFT)
Number of subjects: 0
Study 28676782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 28676782 — intervention group
Group type: COMPARATOR
Intervention: Wait-List Control
Number of subjects: 0
Study 28676842 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS plus optimal drug therapy (DBS+ODT)
Number of subjects: 29
Study 28676842 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 29
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin monotherapy
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrate monotherapy
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily drug intake
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of ApoA1
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic Syndrome
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CV risk
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgot to take medication
Number of subjects: 3338
Study 28677510 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopped medication when cholesterol normal
Number of subjects: 3338
Study 28678012 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal laparoscopic nephrectomy (Group T)
Number of subjects: 40
Study 28678012 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic nephrectomy (Group R)
Number of subjects: 40
Study 28678647 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel, liquid cleanser, and moisturizer SPF 30
Number of subjects: 50
Study 28678647 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Number of subjects: 50
Study 28678771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D <50 nmol/l)
Number of subjects: 568
Study 28678771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D ≥75 nmol/l)
Number of subjects: 568
Study 28678771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status (25(OH)D 50-74.9 nmol/l)
Number of subjects: 568
Study 28679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical functioning
Number of subjects: 714
Study 28679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional health
Number of subjects: 714
Study 28679361 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning
Number of subjects: 714
Study 28679389 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Planning (FP) use
Number of subjects: 240
Study 28679389 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of long-acting reversible contraceptives or permanent methods (LARC-PM)
Number of subjects: 240
Study 28679389 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of long-term method use
Number of subjects: 240
Study 28679389 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data on contraceptive choices
Number of subjects: 240
Study 28679598 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-Ld (12.5 mg/kg)
Number of subjects: 18
Study 28679598 — intervention group
Group type: EXPERIMENTAL
Intervention: MP-Hd (17.5 mg/kg)
Number of subjects: 18
Study 28679598 — intervention group
Group type: COMPARATOR
Intervention: LD+DDCI (3.5 mg/kg)
Number of subjects: 18
Study 28679598 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-DDCI (17.5 mg/kg)
Number of subjects: 18
Study 28679598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28679611 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0
Study 28679611 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28679644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone plus Bevacizumab
Number of subjects: 30
Study 28679676 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk stratification pathway using transient elastography and hepatologists
Number of subjects: 0
Study 28679676 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 28680717 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 127
Study 28680717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 28680917 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 552
Study 28680916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid (LA) 1,200 mg daily
Number of subjects: 51
Study 28680916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 28680960 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 322
Study 28681650 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 100 mg
Number of subjects: 37
Study 28681650 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 200 mg
Number of subjects: 37
Study 28681650 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 400 mg
Number of subjects: 37
Study 28682105 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion regulation difficulties
Number of subjects: 90
Study 28682697 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity activity breaks
Number of subjects: 39
Study 28682697 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity activity breaks
Number of subjects: 39
Study 28682697 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity activity breaks
Number of subjects: 39
Study 28682697 — intervention group
Group type: COMPARATOR
Intervention: Screen-time breaks
Number of subjects: 39
Study 28682736 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal treadmill testing
Number of subjects: 0
Study 28682807 — intervention group
Group type: EXPERIMENTAL
Intervention: New prediction model combining colonoscopic, laboratory, and radiologic parameters.
Number of subjects: 80
Study 28682807 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopic scoring for differentiation.
Number of subjects: 80
Study 28682807 — intervention group
Group type: EXPERIMENTAL
Intervention: CD prediction score (from -2 to 2).
Number of subjects: 80
Study 28682807 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristic curve of the score.
Number of subjects: 80
Study 28683470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 343
Study 28683470 — intervention group
Group type: EXPERIMENTAL
Intervention: Model combining osteopontin, interleukin-6, TIMP-1, tumour burden, and selected clinical criteria
Number of subjects: 343
Study 28683470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 28683732 — intervention group
Group type: EXPERIMENTAL
Intervention: Common treatment regimens for AIS
Number of subjects: 10000
Study 28683732 — intervention group
Group type: EXPERIMENTAL
Intervention: Different treatment regimens for AIS
Number of subjects: 10000
Study 28683732 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events and complications
Number of subjects: 10000
Study 28683732 — intervention group
Group type: EXPERIMENTAL
Intervention: TOAST classification
Number of subjects: 10000
Study 28683743 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy measured by the Newest Vital Sign (NVS)
Number of subjects: 247
Study 28683745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapeutic intervention for 12 weeks
Number of subjects: 30
Study 28684262 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised solid test meal (STM) during high-resolution manometry (HRM)
Number of subjects: 750
Study 28684261 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers (HRM with SWS and rice STM)
Number of subjects: 179
Study 28684261 — intervention group
Group type: COMPARATOR
Intervention: Patients with major motility disorders
Number of subjects: 179
Study 28684261 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy volunteers
Number of subjects: 179
Study 28684261 — intervention group
Group type: COMPARATOR
Intervention: Patients with dysphagia
Number of subjects: 179
Study 28684261 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM with SWS and rice STM
Number of subjects: 179
Study 28684371 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine therapy
Number of subjects: 133
Study 28684537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg by mouth on days 1 to 21), bortezomib (1.0 mg/m2 IV or subcutaneous), dexamethasone
Number of subjects: 0
Study 28684537 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28685151 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 820
Study 28685151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower parity and higher educational levels
Number of subjects: 820
Study 28685159 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular screening using Ion Torrent sequencing platform
Number of subjects: 41
Study 28685159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion Torrent sequencing
Number of subjects: 41
Study 28685159 — intervention group
Group type: EXPERIMENTAL
Intervention: Illumina sequencing technology for validation
Number of subjects: 41
Study 28685159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion Torrent sequencing for copy number aberrations
Number of subjects: 41
Study 28685410 — intervention group
Group type: EXPERIMENTAL
Intervention: Youths with ASD
Number of subjects: 198
Study 28685410 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaffected siblings
Number of subjects: 198
Study 28685410 — intervention group
Group type: COMPARATOR
Intervention: Typically Developing Controls (TD)
Number of subjects: 198
Study 28685973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI (2 mg)
Number of subjects: 375
Study 28685973 — intervention group
Group type: COMPARATOR
Intervention: Exenatide BID (10 μg)
Number of subjects: 375
Study 28685973 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QWS-AI
Number of subjects: 375
Study 28686124 — intervention group
Group type: EXPERIMENTAL
Intervention: Convection-enhanced delivery (CED) with a radiolabeled antibody
Number of subjects: 1
Study 28687077 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of ITLN1 after myocardial ischemia
Number of subjects: 140
Study 28687077 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA expression of ITLN1 in left ventricular tissue after acute ischemia
Number of subjects: 140
Study 28687231 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study 28687231 — intervention group
Group type: COMPARATOR
Intervention: Different controller therapies
Number of subjects: 0
Study 28687349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung cancer screening and tobacco cessation program; details on dosage and duration not available.
Number of subjects: 0
Study 28687349 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not available.
Number of subjects: 0
Study 28687625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (OFA) infusion at an accelerated regimen: 300 mg on week 1 day 1, 1,000 mg on week 1 day 3, 2,000 mg on week 2 day 1, followed by weekly infusions for 8 weeks and monthly for 4 months.
Number of subjects: 34
Study 28687627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib and capecitabine combination therapy
Number of subjects: 15
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS prevalence in men
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS prevalence in women
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: LUTS prevalence by age
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of all three ICS symptom groups
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: Most prevalent symptoms
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: Most bothersome symptoms
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: IPSS scores
Number of subjects: 8284
Study 28687936 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare visits due to urinary symptoms
Number of subjects: 8284
Study 28688730 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical Orders for Scope of Treatment (MOST) documentation
Number of subjects: 370
Study 28689185 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred integrated heart failure and palliative care at home
Number of subjects: 12
Study 28689278 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum total Homocysteine (tHcy) measured at 15-19 weeks
Number of subjects: 500
Study 28689278 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery (Ut-A) Doppler performed at 18-22 weeks
Number of subjects: 500
Study 28689278 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tHcy assessment and Ut-A Doppler
Number of subjects: 500
Study 28689333 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct exposure to ribavirin during pregnancy or 6 months prior (85 women)
Number of subjects: 272
Study 28689333 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect exposure to ribavirin through male partners (95 women)
Number of subjects: 272
Study 28690539 — intervention group
Group type: EXPERIMENTAL
Intervention: NeurimmiRs intervention (specific details not provided)
Number of subjects: 0
Study 28690539 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 28690586 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy (radiotherapy and chemotherapy)
Number of subjects: 50
Study 28690642 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 448
Study 28690642 — intervention group
Group type: COMPARATOR
Intervention: Long-term prophylaxis (LTP)
Number of subjects: 448
Study 28690682 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM-MNCs transplantation
Number of subjects: 7
Study 28690851 — intervention group
Group type: EXPERIMENTAL
Intervention: ER + M group (emotion regulation and mindfulness skills)
Number of subjects: 75
Study 28690851 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 75
Study 28691333 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas-based cryotherapy
Number of subjects: 0
Study 28691333 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal coagulation
Number of subjects: 0
Study 28691436 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated at day 0 of AHI; specific dosage not mentioned.
Number of subjects: 265
Study 28691436 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated AHI)
Number of subjects: 265
Study 28691931 — intervention group
Group type: COMPARATOR
Intervention: Topical gentamicin (0.1% ointment applied 3 times daily for 2 weeks)
Number of subjects: 5
Study 28691931 — intervention group
Group type: COMPARATOR
Intervention: Intradermal gentamicin (8 mg solution injected daily for 2 days)
Number of subjects: 5
Study 28691931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (topical and intradermal)
Number of subjects: 5
Study 28692407 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-assisted treatment (MAT)
Number of subjects: 440
Study 28692407 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient counseling only
Number of subjects: 440
Study 28692407 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment
Number of subjects: 440
Study 28692407 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal treatment (Narcotics Anonymous/Alcoholics Anonymous or halfway house)
Number of subjects: 440
Study 28692407 — intervention group
Group type: EXPERIMENTAL
Intervention: No postdetoxification treatment
Number of subjects: 440